82,095 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 82,095 shares of the company’s stock, valued at approximately $3,231,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Thrivent Financial for Lutherans increased its stake in shares of CRISPR Therapeutics by 1.0% during the third quarter. Thrivent Financial for Lutherans now owns 47,696 shares of the company’s stock worth $2,241,000 after purchasing an additional 473 shares during the period. Advisors Asset Management Inc. raised its position in CRISPR Therapeutics by 3.7% in the third quarter. Advisors Asset Management Inc. now owns 9,669 shares of the company’s stock valued at $454,000 after purchasing an additional 342 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in CRISPR Therapeutics by 0.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock worth $34,025,000 after buying an additional 6,635 shares during the period. Independent Advisor Alliance increased its holdings in CRISPR Therapeutics by 29.2% in the third quarter. Independent Advisor Alliance now owns 7,719 shares of the company’s stock valued at $363,000 after purchasing an additional 1,745 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after acquiring an additional 231 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $38.04 on Friday. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $70.12. The company has a market capitalization of $3.26 billion, a P/E ratio of -8.70 and a beta of 1.77. The firm’s 50 day simple moving average is $43.17 and its 200 day simple moving average is $45.23.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now directly owns 77,530 shares of the company’s stock, valued at approximately $3,288,822.60. This trade represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 over the last 90 days. Insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CRSP. JMP Securities reissued a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $60.00 to $99.00 in a report on Friday, February 14th. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. The Goldman Sachs Group dropped their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Finally, Morgan Stanley increased their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.